MSD Executive Shows MEPs How Brexit Will Hit Pharma Supply Chains
Executive Summary
A senior MSD executive has outlined the impact that Brexit could have on global supply chains, regulatory cooperation and research, at a hearing of the European Parliament’s ENVI committee. Another UK parliamentary committee is to hear industry’s concerns on Dec. 5.
You may also be interested in...
EMA Explains How To Make Brexit-Related MA Changes, As Industry Bodies Urge Transition Period
The EMA has produced further guidance for pharmaceutical companies on the changes they will need to make as a result of Brexit, focusing on activities such as transfers of marketing authorizations and orphan designations, and changes to personnel responsible for pharmacovigilance and batch recalls. Meanwhile, UK and European industry bodies say there is not enough time to make the necessary changes and that a transition period is needed.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.